Pan Cancer

Guiding treatment for solid tumors

In a rapidly changing landscape of genetic technology and cancer treatment options, the journey patients take through diagnosis and treatment is highly individual. At Mayo Clinic, we recognize a one-size-fits-all approach doesn't meet the needs of every patient. Multiple factors, such as history, diagnosis, specimen availability, and prognosis affect which test a patient receives.

PAN CANCER test menu

Pan Cancer

Our comprehensive MayoComplete solid tumor panel analyzes 515 genes for mutations, rearrangements, and/or amplifications, as well as evaluates for tumor mutation burden (TMB) and microsatellite instability (MSI) status to provide detailed insights on diagnosis, prognosis, and treatment response. Because obtaining sufficient tissue for multiple molecular and histological tests can be challenging, we’ve optimized specimen requirements by reducing the amount of FFPE tissue required and accept cytology as an alternative specimen type.

Key testing


  • Guides treatment options, including targeted and immunotherapies.
  • Can assist in determining eligibility for clinical trials.
  • Results interpreted and analyzed by Mayo Clinic geneticists, pathologists, and clinicians.



Fill out the form below and one of our specialists will be in touch.

(BETA) Choose a language to view this content in:
About the translation.